Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Endo International PLC is a specialty pharmaceutical company with a considerable presence in pain management, urology, orthopedics, endocrinology, bariatrics, and others. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceut... Endo International PLC is a specialty pharmaceutical company with a considerable presence in pain management, urology, orthopedics, endocrinology, bariatrics, and others. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. Some of its products include XIAFLEX, SUPPRELIN, PERCOCET, TESTOPEL, VASOSTRICT, ADRENALIN, and APLISOL. The majority of its revenue comes from the United States. Show more
Endo Presents New Data at the American Orthopaedic Foot & Ankle Society Annual Meeting PR Newswire DUBLIN, Sept. 21, 2023 DUBLIN, Sept. 21, 2023 /PRNewswire/ -- Endo International plc (OTC:...
ENDO REPORTS SECOND-QUARTER 2023 FINANCIAL RESULTS PR Newswire DUBLIN, Aug. 8, 2023 DUBLIN, Aug. 8, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) today reported financial results for...
Endo Launches Bivalirudin Injection in Ready-to-Use Vials PR Newswire DUBLIN, July 18, 2023 Only ready-to-use liquid format of bivalirudin on the marketDoes not require reconstitution, dilution...
Endo Presents New Data at the American Podiatric Medical Association Annual Meeting PR Newswire DUBLIN, July 13, 2023 DUBLIN, July 13, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ...
Endo Launches PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe PR Newswire DUBLIN, June...
ENDO REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTS PR Newswire DUBLIN, May 8, 2023 DUBLIN, May 8, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) today reported financial results for the...
Endo Announces Launch of Argatroban Injection Through Premier's ProRx® Private-Label Program PR Newswire DUBLIN, April 17, 2023 DUBLIN, April 17, 2023 /PRNewswire/ -- Endo International plc (OTC:...
Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Oral Suspension PR Newswire DUBLIN, April 3, 2023 DUBLIN, April 3, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ...
Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants With Plantar Fibromatosis PR Newswire DUBLIN, March 13, 2023 DUBLIN, March 13, 2023...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
